MedTrace Logo

Canadian EdoxAban(Lixiana®) Registry in Patients With ATrial Fibrillation/Flutter With Confirmed ValvUlar HeaRt DiseasE

NCT03488420 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 136

Last updated 2025-04-06

No results posted yet for this study

Summary

The objective of this registry is the characterization of patients with atrial fibrillation (AF) and/ or atrial flutter (AFL) with confirmed VHD who are prescribed edoxaban in a real life clinical setting.

Conditions

  • Atrial Fibrillation and Flutter
  • Valvular Heart Disease

Interventions

DRUG

Edoxaban Pill

Subjects will be taking edoxaban 30 or 60 mg

Sponsors & Collaborators

  • Servier

    collaborator INDUSTRY

  • Montreal Heart Institute

    lead OTHER

Principal Investigators

  • Katia Dyrda, MD · Montreal Heart Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-30
Primary Completion
2025-03-21
Completion
2025-04-03
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03488420 on ClinicalTrials.gov